{"denoms":[{"counts":[{"groupId":"BG000","value":"464"},{"groupId":"BG001","value":"467"},{"groupId":"BG002","value":"931"}],"units":"Participants"}],"groups":[{"description":"Participants randomized to the chemotherapy arm received vinflunine, paclitaxel, or docetaxel per the investigators choice. Vinflunine 320 milligrams per square meter (mg/m\\^2), paclitaxel 175 mg/m\\^2, or docetaxel 75 mg/m\\^2 were administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.","id":"BG000","title":"Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)"},{"description":"Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.","id":"BG001","title":"Atezolizumab"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.3","value":"66.1"},{"groupId":"BG001","spread":"9.6","value":"65.9"},{"groupId":"BG002","spread":"9.4","value":"66.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"103"},{"groupId":"BG001","value":"110"},{"groupId":"BG002","value":"213"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"361"},{"groupId":"BG001","value":"357"},{"groupId":"BG002","value":"718"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"29"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"368"},{"groupId":"BG001","value":"363"},{"groupId":"BG002","value":"731"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"91"},{"groupId":"BG002","value":"171"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"63"},{"groupId":"BG002","value":"118"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"336"},{"groupId":"BG001","value":"335"},{"groupId":"BG002","value":"671"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"70"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"138"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}]}